Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | JUN | P05412 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090682 | 0.77 | CYP1A2 (0.48) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL12090622 | 0.76 | TGFBR1 (0.60) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL12090422 | 0.76 | TGFBR1 (0.72) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL1820552 | 0.75 | CYP1A2 (0.44) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL12090664 | 0.71 | TGFBR1 (0.45) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL12090555 | 0.71 | FGFR1 (0.45) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL12090714 | 0.70 | CYP1A2 (0.42) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL12090685 | 0.69 | CYP1A2 (0.44) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| Tp-008 SCHEMBL29657225 | 0.67 | TGFBR1 (1.00) | CYP1A2TGFBR1CYP3A4HTR2BACVR1B | |
| SCHEMBL12090559 | 0.67 | TGFBR1 (0.45) | TGFBR1CYP3A4ACVR1BACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| WO-2011054433-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | TGFBR1, TGFBR2, TGFB1 | CYP1A2 1818/4885TGFBR1 1/4885CYP3A4 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.